Summary
- Profile Type
- Research & Development Request
- POD Reference
- RDRTR20250721007
- Term of Validity
- 21 July 2025 - 21 July 2026
- Company's Country
- Turkey
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- Spain
- Netherlands
- Switzerland
- Finland
- Ireland
- Denmark
- Germany
- Norway
- France
- Sweden
- United Kingdom
- Belgium
- Austria
- Italy
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A research team is preparing a proposal under the Horizon Europe call “TOOL-01: Enhancing cell therapies with synthetic biology”. We are currently looking for a partner with expertise in cell engineering and functional in vitro validation to contribute to a work package focused on testing gene circuit behavior in relevant cell models. Experience in techniques such as FACS, qRT-PCR, immunostaining, and signal-response analysis is highly desirable.
- Full Description
-
The project focuses on the development of an innovative therapeutic platform that combines synthetic biology tools with advanced in vitro disease models. The aim is to engineer programmable cell systems capable of responding to disease-specific signals in a controlled and precise manner. The proposed approach leverages recent advances in gene circuit design, cell-based delivery mechanisms, and microphysiological validation platforms, with a strong focus on translational potential in complex disease contexts such as those affecting the central nervous system.
Therefore, the university is looking for a partner related to the following subjects:
-One with expertise in AI-driven informatics and computational analysis,
-One with expertise in ethics and regulatory policymaking. - Advantages and Innovations
- The project will offer a novel cell-based therapeutic approach designed to function within physiologically relevant microenvironments. By integrating synthetic biological systems into human-derived cellular platforms, it aims to overcome key limitations of conventional preclinical methods. This strategy will help reduce translational gaps, enable precise modulation of therapeutic responses, and support early identification of safety and efficacy parameters. Ultimately, the project aligns with the increasing need for ethical, next-generation therapeutic solutions that are more predictive, scalable, and compatible with regulatory pathways.
- Technical Specification or Expertise Sought
-
The university is looking for partners as explained below:
-One with expertise in AI-driven informatics and computational analysis,
-One with expertise in ethics and regulatory policymaking. - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- IPR status
- No IPR applied
Partner Sought
- Expected Role of a Partner
-
The university is looking for partners as explained below:
-One with expertise in AI-driven informatics and computational analysis,
-One with expertise in ethics and regulatory policymaking. - Type and Size of Partner
- University
- R&D Institution
- Big company
- SME 11-49
- SME <=10
- SME 50 - 249
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Horizon Europe
- Call title and identifier
-
Horizon-Hlth-2025-01-Tool-01: Enhancing cell therapies with genomic techniques
- Submission and evaluation scheme
-
Single Stage Call
- Anticipated project budget
-
8000000
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
156
- Web link to the call
- https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-HLTH-2025-01-TOOL-01?isExactMatch=true&status=31094502&frameworkProgramme=43108390&callIdentifier=HORIZON-HLTH-2025-01&order=DESC&pageNumber=1&pageSiz=
- Project title and acronym
-
Advanced Human-Based Microphysiological Systems for Predictive Modelling of Oncology Therapies
- Horizon Europe
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 04009 - In vitro Testing, Trials
- 05001002 - In-vitro diagnostics
- 05001001 - Diagnostic services
- 05001003 - Differential diagnosis
- Sector Groups Involved
- Health
- Targeted countries
- Spain
- Netherlands
- Switzerland
- Finland
- Ireland
- Denmark
- Germany
- Norway
- France
- Sweden
- United Kingdom
- Belgium
- Austria
- Italy